All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

CD79B Recombinant Monoclonal Antibody

Promotion
Datasheet
Code CSB-RA004958MA2HU
Size $49.9
Order now
Promotion
CUSABIO Limited Time Offer: 3,000+ Abs from $49.9/100µg or $49.9/100ul.
Image
  • The Binding Activity of Human CD79B with Anti-CD79B recombinant antibody
    Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CD79A(CSB-MP004958HU1) at 2 μg/mL can bind Anti-CD79B recombinant antibody. The EC50 is 3.214-3.642 ng/mL.
  • The Binding Activity of Human CD79A&CD79B with Anti-CD79B recombinant antibody
    Activity:Measured by its binding ability in a functional ELISA. Immobilized Human CD79A&CD79B(CSB-MP5861HU) at 2 μg/mL can bind Anti-CD79B recombinant antibody. The EC50 is 14.85-17.47 ng/mL.
  • The Binding Activity of Human CD79B with Anti-CD79B recombinant antibody
    Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CD79B(CSB-MP004958HU1p7) at 2 μg/mL can bind Anti-CD79B recombinant antibody. The EC50 is 31.97-35.69 ng/mL.
  • Untransfected HEK-293T cells (green line) and transfected Human CD79B HEK-293T stable cells (red line) were stained with anti-CD79B antibody(CSB-RA004958MA2HU) (2µg/1*106cells), washed and then followed by APC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
  • Untransfected HEK-293T cells (green line) and transfected Human CD79A&CD79B HEK-293T stable cells (red line) were stained with anti-CD79B antibody(CSB-RA004958MA2HU) (2µg/1*106cells), washed and then followed by APC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
P40259
Target Names
CD79B
Alternative Names
AGM6 antibody; B cell antigen receptor complex associated protein beta chain antibody; B cell specific glycoprotein B29 antibody; B-cell antigen receptor complex-associated protein beta chain antibody; B-cell-specific glycoprotein B29 antibody; B29 antibody; B29/Ig-beta/CD79b antibody; CD 79b antibody; CD79b antibody; CD79b antigen (immunoglobulin associated beta) antibody; CD79b antigen antibody; CD79b molecule antibody; CD79b molecule immunoglobulin associated beta antibody; CD79b protein antibody; CD79B_HUMAN antibody; Ig beta antibody; Ig-beta antibody; IGB antibody; Igbeta antibody; Immunoglobulin associated B29 antibody; Immunoglobulin associated B29 protein antibody; Immunoglobulin associated beta antibody; Immunoglobulin associated protein antibody; Immunoglobulin-associated B29 protein antibody; MGC108607 antibody
Species Reactivity
Human
Immunogen
Recombinant Human CD79B protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
hIgG1
Clone No.
8E9
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, FC
Recommended Dilution
Application Recommended Dilution
ELISA 1:5000-1:50000
FC 1:50-1:200
Protocols
ELISA Protocol
Flow Cytometry (FC) Protocol
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

CD79B, also known as Ig-beta or B29, serves as an essential component of the B-cell antigen receptor complex, where it pairs with CD79A to form the signaling heterodimer that transduces activation signals following antigen engagement. This transmembrane protein plays a fundamental role in B-cell development, activation, and differentiation, making it a critical marker for studying B-cell biology and an important target in hematological malignancy research, particularly in B-cell lymphomas and leukemias where CD79B mutations have been identified as drivers of disease.

This recombinant monoclonal antibody, clone 8E9, offers the consistency and reliability that demanding research applications require. Produced using recombinant technology with a defined human IgG1 framework, this antibody provides sequence-level reproducibility between lots, ensuring your experimental results remain comparable across extended studies. The antibody was generated against recombinant human CD79B protein and has been validated for human reactivity.

Functional ELISA validation demonstrates robust binding activity, with the antibody recognizing both isolated CD79B and the CD79A/CD79B heterodimer complex. EC50 values in the low nanogram per milliliter range confirm high-affinity binding suitable for sensitive detection applications. Flow cytometry validation using HEK-293T cells stably transfected with human CD79B, as well as cells expressing the CD79A/CD79B complex, shows clear discrimination between transfected and untransfected populations, confirming specific recognition of cell-surface CD79B.

The unconjugated format and affinity-purified preparation provide flexibility for researchers investigating B-cell signaling pathways, immune cell phenotyping, or therapeutic antibody development targeting the B-cell receptor complex.

Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

CD79B Antibodies

CD79B Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
Gene References into Functions
  1. CD79B mutations were found in six of 19 cases (31.6%) of primary CNS diffuse large B-cell lymphoma , all in the Y196 mutation hotspot PMID: 28856744
  2. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of CD79B mutations. PMID: 28803429
  3. hotspot mutations of CD79B Y196 and MYD88 L265 may serve as a genetic hallmark for primary central nervous system lymphoma PMID: 26111727
  4. CD79B overexpression leading to activation of AKT/MAPK is a potential mechanism underlying primary ibrutinib resistance in ABC-DLBCL, and support its utility as an effective biomarker to predict therapeutic response to ibrutinib. PMID: 26699656
  5. Novel CD79B variations in mature B-cell non-Hodgkin's lymphoma patients were detected. PMID: 27010137
  6. MYD88 L265P and CD79B mutations were frequently detected in primary breast diffuse large B-cell lymphoma. PMID: 26752547
  7. Oncogenic CD79B mutation is associated with primary diffuse large B-cell lymphomas of central nervous system. PMID: 25347427
  8. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. PMID: 25501023
  9. Abberant expression of CD79b in non-B cells caused unwanted reactivity, rendering CD79b unsuitable for T-cell receptor - based immunotherapies. PMID: 25414443
  10. results suggest that MYD88 mutations, and to a lesser extent CD79B mutations, are important drivers of lymphomagenesis in PTL PMID: 24253023
  11. CD79B and MYD88 mutations are associated with an older age at onset in diffuse large b-cell lymphoma with a significant overlap, which did not affect the outcome of the disease. PMID: 24444466
  12. CD79B point mutation is associated with B-cell non-Hodgkin lymphomas. PMID: 23361872
  13. Data indicate a secondary promoter located within exon 2 maintained full levels and specificity of hCD79b transcription. PMID: 23649625
  14. The present study failed to find any mut-ation in MYD88, CARD11 or CD79B in ocular MALT lymphoma. PMID: 22808296
  15. Expression of CD79b is downregulated in both plasma cells and plasma cell myeloma. PMID: 21355953
  16. The B cell-specific B29 gene promoter is transactivated in B and non-B cells by cotransfection with the B cell-specific octamer cofactor gene, Bob1 (OCA-B/OBF-1). PMID: 11907094
  17. The alternative splicing variant DeltaCD79b may be a powerful modulator of BCR signaling that may play an important role in normal and malignant B cell PMID: 12384401
  18. Following B cell receptor cross-linking, a significant amount of the transgenic Ig beta pool (together with Ig alpha) remains on the B cell surface independent of surface immunoglobulin internalization. PMID: 15661909
  19. Results reveal tissue-specific patterns of chromatin structures and transcriptional controls at the CD79b/GH locus in B cells distinct from those in the pituitary gland and placenta. PMID: 16847312
  20. establish a strong linkage between Igbeta mRNA expression and somatic hypermutation in chronic lymphocytic leukaemia and highlight the complex relationships between biochemical parameters and clinical status in this disease PMID: 17315213
  21. Ig-beta was phosphorylated in about 20% of myeloma IgG BCR isolates, but not in normal B-cell controls. PMID: 17701175
  22. These results indicate that mutations in Igbeta can cause agammaglobulinemia in man. PMID: 17709424
  23. mutations responsible for agammaglobulinemia in humans PMID: 18978465

Show More

Hide All

Involvement in disease
Agammaglobulinemia 6, autosomal recessive (AGM6)
Subcellular Location
Cell membrane; Single-pass type I membrane protein.
Tissue Specificity
B-cells.
Database Links

HGNC: 1699

OMIM: 147245

KEGG: hsa:974

STRING: 9606.ENSP00000376544

UniGene: Hs.89575

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
CD79A and CD79B: Key Targets in B Cell Signaling Pathways and Therapeutic Potential Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?
Related pathways
B cell receptor signaling pathway Cell markers Target Therapy
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
No. 269, Shendun 5th Road, Donghu Hi-Tech Development Area, Hubei Province, 430206, P.R.China
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*